XIAOMI-W
01810
BABA-W
09988
MEITUAN-W
03690
4
MIXUEGROUP
02097
5
TENCENT
00700
HK Stock MarketDetailed Quotes
01696 SISRAM MED
- 3.940
- +0.190+5.07%
Market Closed Feb 26 16:08 CST
1.85BMarket Cap10.03P/E (TTM)
4.020High3.710Low2.54MVolume3.750Open3.750Pre Close9.85MTurnover0.54%Turnover Ratio7.49P/E (Static)468.34MShares4.95052wk High0.52P/B1.85BFloat Cap2.63252wk Low0.16Dividend TTM468.34MShs Float34.442Historical High0.158Dividend LFY8.27%Amplitude1.552Historical Low3.881Avg Price400Lot Size4.01%Div YieldTTM4.01%Div Yield LFY
SISRAM MED News
FuRui Medical Technology (01696.HK): Leading global energy source equipment to accelerate the construction of a beautiful, healthy and diversified ecosystem
FuRui Medical Technology (01696.HK): The medical and aesthetic business is rising steadily, and the Asia-Pacific and European markets continue to gain strength
FuRui Medical Technology (1696.HK): Energy Source Medical and Aesthetic Leaders Build a Big Medical and Aesthetic Ecological Platform
Fu Rui Medical Technology (01696.HK): High interest rates affect the pace of growth in North America 24H2 botulinum toxin is expected to be approved
Fu Rui Medical Technology (01696.HK): 24H1 performance, short-term pressure to focus on the progress of the injection filling pipeline
FuRui Medical Technology (01696.HK): Short-term performance disrupts during the transition period, concerns the injection sector is ready to go
FuRui Medical Technology (01696.HK): 2023 results are under pressure, and we expect China to strengthen the registration and filling business
FuRui Medical Technology (01696.HK): Short-term performance under multiple factors, pressure-pressurized injection lines are about to be approved domestically
Fu Rui Medical Technology (01696.HK): Leading medical and aesthetic energy source equipment to build a beautiful and healthy ecosystem
Fu Rui Medical Technology (1696.HK): The macro environment puts short-term pressure on mid-term results and the beauty ecosystem does not change its resilience
Fu Rui Medical Technology (01696.HK) 2023 Interim Report Review: Macro Environmental Factors and Channel Adjustments Drag Down Some Regional Majority Shareholders to Propose Repurchase, Showing Confidence
Fukui Medical Technology (1696.HK): Business transformation consolidation has led to slight adjustments in the short term and long-term development can still be expected
Fu Rui Medical Technology (1696.HK): 23H1 performance is temporarily under pressure and direct sales construction continues to strengthen
Fu Rui Medical Technology (01696.HK) Company Review: Mergers and Acquisitions Increase Direct Sales in China to Boost Gross Profit Growth
FuRui Medical Technology (01696.HK): Continued direct sales channel layout and strength of multiple business lines
Fu Rui Medical Technology (1696.HK): Medical, aesthetic and health platform with global channel layout and full business coverage
FuRui Medical Technology (1696.HK) In-depth Report: Leading Medical and Aesthetic Energy Source Products, Injection Products Ready to Go
Fu Rui Medical Technology (01696.HK): Another major drop in medical and aesthetic botulinum toxin listing application accepted
FuRui Medical Technology (01696.HK): China's direct sales layout made significant progress and acquired ALMALASERS distribution business
Furui Medical Technology (1696.HK): Direct sales continue to deepen in line with expectations